ScreenerHero
VETOVetoquinol SA
EPA · FR · Healthcare · Drug Manufacturers - Specialty & Generic · vetoquinol.com
70.50EUR-0.70%Mkt Cap: 890.80M $P/E: 14.27

Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Paci…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap890.80M $
Enterprise Value673.32M $
Revenue (TTM)571.40M $
Gross Profit426.98M $
Net Income (TTM)62.35M $
Revenue/Share49.17 USD
Last Price70.50 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees2.4K
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINFR0004186856
Valuation
P/E (Trailing)14.27
P/E (Forward)12.58
PEG3.80
EV/EBITDA5.99
EV/Revenue1.18
P/S1.57
P/B1.47
EPS (TTM)4.94
EPS (Forward)5.64
52W Range
67.3013% of range91.50
52W High91.50 EUR
52W Low67.30 EUR
Profitability
Gross Margin74.73%
Oper. Margin16.82%
EBITDA Margin19.68%
Profit Margin10.91%
ROE9.70%
ROA7.51%
Growth
Revenue Growth-2.40%
Earnings Growth-5.10%
Cash Flow & Leverage
Operating CF78.34M $
CapEx (TTM)22.53M $
FCF Margin9.26%
FCF Yield5.94%
Net Debt-223.68M $
Net Debt/EBITDA-1.99
Balance Sheet
Debt/Equity0.03
Current Ratio3.08
Quick Ratio2.21
Book Value/Sh48.21 EUR
Cash/Share19.02 EUR
Dividends
Fwd Div Rate0.9300 EUR
Trail. Div Rate0.9300 EUR
Div. Yield1.30%
5Y Avg Yield0.89%
Payout Ratio18.02%
Ex-Div DateJun 3, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)90.38 EUR
Upside (mean)+28.2%
Target Range80.00 EUR – 110.00 EUR
€80.00+28.2% to mean€110.00
# Analysts4
Ownership
Shares Out.11.62M
Float3.65M
Insiders67.01%
Institutions12.67%
Technical
SMA 5071.40 (-1.3%)
SMA 20077.12 (-8.6%)
Beta0.88
S&P 52W Chg18.16%
Avg Vol (30d)5.08K
Avg Vol (10d)15.95K
Technical Indicators
RSI (14)45.3
MACD-0.1939
MACD Signal-0.0675
MACD Hist.-0.1264
BB Upper73.55 EUR
BB Middle71.95 EUR
BB Lower70.36 EUR
BB Width4.42%
ATR (14)1.150 EUR
Vol Ratio (20d)0.46x